489 related articles for article (PubMed ID: 15841432)
1. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
3. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
5. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
7. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
8. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
9. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience.
Haus O; Kotlarek-Haus S; Potoczek S; Czarnecka M; Duszenko E; Makowska I; Mirowska N; Kuliczkowski K
Neoplasma; 2006; 53(2):136-43. PubMed ID: 16575469
[TBL] [Abstract][Full Text] [Related]
12. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
[TBL] [Abstract][Full Text] [Related]
14. [Cytogenetic study of 93 myelodysplastic syndromes].
Solé F; Woessner S; Florensa L; Pérez-Losada A; Acín P; Besses C; García-Eroles L; Sans-Sabrafen J
Med Clin (Barc); 1998 Jan; 110(3):94-8. PubMed ID: 9534140
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
Mecucci C
Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
[TBL] [Abstract][Full Text] [Related]
17. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
[TBL] [Abstract][Full Text] [Related]
18. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
Slovak ML; O'Donnell M; Smith DD; Gaal K
Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
[TBL] [Abstract][Full Text] [Related]
19. Hematologic and cytogenetic analyses of 99 cases of de novo myelodysplastic syndromes.
D'Emilio A; Montaldi A; Stella M; Celli P; Guercini N; Tremul L; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):61-5. PubMed ID: 8039762
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the prognosis of patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Germing U; Ganser A
Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]